Clinical trials
Observational Metabolic Syndrome trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 16 |
| Completed | 6 |
| Active, not recruiting | 2 |
| Recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| John Sievenpiper | 9 |
| University of Toronto | 6 |
| Laval University | 5 |
| Cardiovascular Research New Brunswick | 1 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | 1 |
| University Health Network, Toronto | 1 |
| University of British Columbia | 1 |
| University of Manitoba | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Metabolic Syndrome | 26 |
| Obesity | 16 |
| Cardiovascular Diseases | 14 |
| Diabetes Mellitus | 14 |
| Overweight | 12 |
| Prediabetic State | 11 |
| Insulin Resistance | 10 |
| Body Weight | 9 |
| Hypertension | 9 |
| Dyslipidemias | 8 |
Trials
Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.